These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 15722391)

  • 1. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.
    Dupont P; Hocquet D; Jeannot K; Chavanet P; Plésiat P
    J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Low-level resistance to fluoroquinolones conferred by efflux overproduction in Pseudomonas aeruginosa: clinical significance and routine detection].
    Hocquet D; Patry I; Dupont P; Bize M; Jeannot K; Chavanet P; Plésiat P
    Pathol Biol (Paris); 2005; 53(8-9):495-9. PubMed ID: 16203109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MexAB-OprM hyperexpression in NalC-type multidrug-resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720-PA3719.
    Cao L; Srikumar R; Poole K
    Mol Microbiol; 2004 Sep; 53(5):1423-36. PubMed ID: 15387820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype.
    Wolter DJ; Black JA; Lister PD; Hanson ND
    J Antimicrob Chemother; 2009 Aug; 64(2):294-300. PubMed ID: 19468029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The roles of active efflux system overexpression and outer membrane protein OprD deficiency or loss in carbapenem resistance of Pseudomonas aeruginosa].
    Yi MY; Wang PY; Huang HJ; Liu YC
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(7):457-62. PubMed ID: 16677571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC; Wang HB; Sun ZY; Shen ZY
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.
    Hocquet D; Nordmann P; El Garch F; Cabanne L; Plésiat P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1347-51. PubMed ID: 16569851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Two efflux systems expressed simultaneously in clinical Pseudomonas aeruginosa].
    Hocquet D; Llanes C; Patry I; El Garch F; Plésiat P
    Pathol Biol (Paris); 2004 Oct; 52(8):455-61. PubMed ID: 15465264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs.
    Lister PD; Wolter DJ; Wickman PA; Reisbig MD
    J Antimicrob Chemother; 2006 May; 57(5):999-1003. PubMed ID: 16513915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital.
    Wolter DJ; Smith-Moland E; Goering RV; Hanson ND; Lister PD
    Diagn Microbiol Infect Dis; 2004 Sep; 50(1):43-50. PubMed ID: 15380277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of efflux pump MexAB-OprM and OprD of Pseudomonas aeruginosa strains isolated from clinical samples using qRT-PCR.
    Arabestani MR; Rajabpour M; Yousefi Mashouf R; Alikhani MY; Mousavi SM
    Arch Iran Med; 2015 Feb; 18(2):102-8. PubMed ID: 25644798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug screening model acting on out-membrane protein OprM in pseudomonas aeruginosa efflux pump system].
    Tian R; Yu LY; Xiao CL; Zuo L; Yao TJ; Yang LX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):359-63. PubMed ID: 15379256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin.
    Hocquet D; Roussel-Delvallez M; Cavallo JD; Plésiat P
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1582-3. PubMed ID: 17220417
    [No Abstract]   [Full Text] [Related]  

  • 15. In vivo impact of the MexAB-OprM efflux system on beta-lactam efficacy in an experimental model of Pseudomonas aeruginosa infection.
    Boutoille D; Jacqueline C; Le Mabecque V; Potel G; Caillon J
    Int J Antimicrob Agents; 2009 May; 33(5):417-20. PubMed ID: 19157801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contributions of IMP-10 metallo-beta-lactamase, the outer membrane barrier and the MexAB-OprM efflux system to high-level carbapenem resistance in Pseudomonas aeruginosa.
    Zhao WH; Hu Z; Chen G; Ito R; Hu ZQ
    Chemotherapy; 2009; 55(3):168-74. PubMed ID: 19420932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa.
    Pan YP; Xu YH; Wang ZX; Fang YP; Shen JL
    Arch Microbiol; 2016 Aug; 198(6):565-71. PubMed ID: 27060003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
    Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
    J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combined phenotypic and genotypic method for the detection of Mex efflux pumps in Pseudomonas aeruginosa.
    Mesaros N; Glupczynski Y; Avrain L; Caceres NE; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2007 Mar; 59(3):378-86. PubMed ID: 17289770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.